Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today the presentation of an original communication at The EASL Congress held in Vienna and organized by the European Association for the Study of Liver Diseases (EASL).
Barcelona Liver Bioservices (BLB) announced today the presentation of an original communication at the annual meeting of the American Association for the Study of the Liver (AASLD), held as The Liver Meeting Digitial Experience.
Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “The pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease” in the peer-reviewed scientific journal Journal of Hepatology.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with Surrozen, a biotech company developing tissue-specific antibodies that have the potential to regenerate tissue in situations of serious diseases.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with GAT Therapeutics, an early stage biopharma targeting fibrosis and age-related diseases.
Barcelona Liver Bioservices (BLB) announced today the presentation of two communications at the annual meeting of the American Association for the Study of the Liver (AASLD), held in Boston, Massachusetts.
Barcelona Liver Bioservices announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients.
Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease” in the peer-reviewed journal Cells.
The study characterizes the effects, and underlying mechanisms, of the pan-caspase inhibitor emricasan on portal hypertension, fibrosis and liver cells phenotype in pre-clinical models of advanced cirrhosis.
Barcelona Liver Bioservices (BLB) announced today the presentation of two posters at the annual meeting of the European Association for the Study of the Liver (EASL), held in Vienna.
Barcelona Liver Bioservices (BLB), CRO especially focused on the field of Hepatology, announced today its participation in the upcoming International Liver Congress (ILC) 2019 – the annual meeting of the European Association for the Study of the Liver (EASL) that will take place in Vienna in April 10-14th 2019.
Barcelona Liver Bioservices (BLB) announced today the presentation of a poster describing the mechanisms of action of emricasan in liver cirrhosis at the 69th annual meeting of the American Association for the Study of the Liver (AASLD), held in San Fransico, CA.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.
The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
Barcelona Liver Bioservices (BLB) announced today the presentation of a poster introducing the BLB’s proprietary experimental model of nonalcoholic steatohepatitis (NASH) at the 42nd annual meeting of the Spanish Association for the Study of the Liver (AEEH), held in Madrid, Spain.
Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).
Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.
Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Conatus Pharmaceuticals, biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.
Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.